FN2 Earnings Intelligence
Quest Diagnostics Incorporated balance sheet (quarterly)
Quest Diagnostics Incorporated (DGX) Balance Sheet (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 | 12/30/2026 est. | 3/30/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $319 | $432 | $393 | $626 | $797 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $2,761 | $2,816 | $2,895 | $3,043 | $3,097 | $3,038.8 | $3,030.8 |
| % Growth | - | - | - | - | - | - | 4.7% |
| Gross Profit | $943 | $949 | $942 | $1,027 | $1,042 | - | - |
| % Margin | 34.2% | 33.7% | 32.5% | 33.7% | 33.6% | - | - |
| EBITDA | $581 | $528 | $546 | $605 | $626 | - | - |
| % Margin | 21.0% | 18.8% | 18.9% | 19.9% | 20.2% | - | - |
| Net Income | $282 | $245 | $252 | $320 | $312 | - | - |
| % Margin | 10.2% | 8.7% | 8.7% | 10.5% | 10.1% | - | - |
| Diluted EPS | $2.47 | $2.16 | $2.24 | $2.84 | $2.78 | $2.68 | $2.71 |
| % Growth | - | - | - | - | - | - | 21.1% |
| Operating Cash Flow | - | - | $278 | - | - | - | - |
| CapEx | - | - | $114 | - | - | - | - |
| Free Cash Flow | - | - | $164 | - | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 | 12/30/2026 est. | 3/30/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $2,761 | $2,816 | $2,895 | $3,043 | $3,097 | $3,038.8 | $3,030.8 |
| Gross Profit | $943 | $949 | $942 | $1,027 | $1,042 | - | - |
| EBITDA | $581 | $528 | $546 | $605 | $626 | - | - |
| Net Income | $282 | $245 | $252 | $320 | $312 | - | - |
| Diluted EPS | $2.47 | $2.16 | $2.24 | $2.84 | $2.78 | $2.68 | $2.71 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $319 | $432 | $393 | $626 | $797 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | - | - | $5,632 | $5,540 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $278 | - | - |
| Capital Expenditure | - | - | $114 | - | - |
| Free Cash Flow | - | - | $164 | - | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 34.2% | 33.7% | 32.5% | 33.7% | 33.6% |
| EBITDA Margin | 21.0% | 18.8% | 18.9% | 19.9% | 20.2% |
| Net Margin | 10.2% | 8.7% | 8.7% | 10.5% | 10.1% |
| FCF Margin | - | - | 5.7% | - | - |
| Diluted EPS Growth | - | - | - | - | - |
Get the DGX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.